Prevalence of Antibiotic Resistance Over Time in a Third-Level University Hospital
暂无分享,去创建一个
B. Cesana | M. Liberto | N. Marascio | A. Bruni | E. Garofalo | F. Longhini | G. Matera | C. Torti | M. Mazzitelli | E. Trecarichi | F. Serapide | C. Peronace | A. Giancotti | A. Quirino | C. Costa | V. Scaglione | R. Lionello | V. La Gamba | Daniela Procopio | L. Gallo | P. Fusco | C. Davoli | M. Reale
[1] Antimicrobial Resistance in the EU/EEA , 2022 .
[2] M. Bassetti,et al. Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study , 2021, BMC Infectious Diseases.
[3] G. Ripabelli,et al. Healthcare-Associated Infections and Antibiotics Consumption: A Comparison of Point Prevalence Studies and Intervention Strategies , 2021, Hospital topics.
[4] Songzhe He,et al. Distribution and Carbapenem Susceptibility of Gram-Negative ESKAPE Pathogens in Hospitalized Patients from Three General Hospitals. , 2021, Clinical laboratory.
[5] S. K. Mishra,et al. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital , 2019, Infection and drug resistance.
[6] G. Lina,et al. Trends in Antibiotic Consumption and Resistance in France Over 20 Years: Large and Continuous Efforts but Contrasting Results , 2020, Open forum infectious diseases.
[7] A. Kharat,et al. Retrospective Analysis on Antimicrobial Resistance Trends and Prevalence of β-lactamases in Escherichia coli and ESKAPE Pathogens Isolated from Arabian Patients during 2000–2020 , 2020, Microorganisms.
[8] Veena P Menon,et al. Clinical efficacy and pharmacokinetics of CMS and colistin in critically ill patients in an Indian hospital with high endemic rates of multidrug-resistant gram-negative bacterial infections-A Prospective Observational Study. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[9] M. Antonelli,et al. Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections , 2020, Annals of Intensive Care.
[10] S. Beatson,et al. Antimicrobial Resistance in ESKAPE Pathogens , 2020, Clinical Microbiology Reviews.
[11] K. Peck,et al. Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] C. Torti,et al. Ceftolozane/tazobactam for difficult-to-treat Pseudomonas aeruginosa infections: a systematic review about its efficacy and safety for off-label indications. , 2020, International journal of antimicrobial agents.
[13] G. Ripabelli,et al. Molecular Epidemiological Insights into Colistin-Resistant and Carbapenemases-Producing Clinical Klebsiella pneumoniae Isolates , 2019, Infection and drug resistance.
[14] L. Marconi,et al. Prognostic Utility of the New Definition of Difficult-to-Treat Resistance Among Patients With Gram-Negative Bloodstream Infections , 2019, Open forum infectious diseases.
[15] P. Navalesi,et al. Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report. , 2019, The Journal of antimicrobial chemotherapy.
[16] P. Courvalin,et al. Population-based inference of aminoglycoside resistance mechanisms in Escherichia coli , 2019, EBioMedicine.
[17] A. Nicolucci,et al. Control of Gram-negative multi-drug resistant microorganisms in an Italian ICU: Rapid decline as a result of a multifaceted intervention, including conservative use of antibiotics. , 2019, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[18] Sameer S. Kadri,et al. External Validation of Difficult-to-Treat Resistance Prevalence and Mortality Risk in Gram-Negative Bloodstream Infection Using Electronic Health Record Data From 140 US Hospitals. , 2019, Open forum infectious diseases.
[19] M. L. Ciofi Degli Atti,et al. [Good practices for the surveillance and control of antimicrobial resistance]. , 2019, Epidemiologia e prevenzione.
[20] S. Antinori,et al. Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase–producing K. pneumoniae , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[21] W. Dunne,et al. Developmental roadmap for antimicrobial susceptibility testing systems , 2018, Nature Reviews Microbiology.
[22] Sameer S. Kadri,et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] G. Kahlmeter,et al. Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[24] A. Focà,et al. Control of carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit of a teaching hospital in Southern Italy , 2016, BMC Infectious Diseases.
[25] S. Pournaras,et al. Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistance. , 2016, International journal of antimicrobial agents.
[26] Matthew H Samore,et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] Karen C Carroll,et al. The Use of a Combination Antibiogram to Assist with the Selection of Appropriate Antimicrobial Therapy for Carbapenemase-Producing Enterobacteriaceae Infections , 2015, Infection Control & Hospital Epidemiology.
[28] M. Kollef,et al. Impact of Sepsis Classification and Multidrug-Resistance Status on Outcome Among Patients Treated With Appropriate Therapy* , 2015, Critical care medicine.
[29] A. Armaganidis,et al. Bloodstream infections in ICU with increased resistance: epidemiology and outcomes. , 2015, Minerva anestesiologica.
[30] Development of a urinary-specific antibiogram for gram-negative isolates: impact of patient risk factors on susceptibility. , 2014, American journal of infection control.
[31] L. Leibovici,et al. Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] Deverick J. Anderson,et al. Ability of an Antibiogram to Predict Pseudomonas aeruginosa Susceptibility to Targeted Antimicrobials Based on Hospital Day of Isolation , 2012, Infection Control & Hospital Epidemiology.
[33] Benjamin Vekhter,et al. Demonstration of the Weighted-Incidence Syndromic Combination Antibiogram: An Empiric Prescribing Decision Aid , 2012, Infection Control & Hospital Epidemiology.
[34] M. Falagas,et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[35] J. Bartlett,et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] L. Rice. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. , 2008, The Journal of infectious diseases.
[37] D. Livermore,et al. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. , 2001, The Journal of antimicrobial chemotherapy.
[38] D. Shlaes. Role of antimicrobial stewardship in prevention and control of antibiotic resistance , 1999, Current infectious disease reports.